|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
$8,123
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Improving T-cell therapies for neuroblastoma
|
5R01CA142636-02
|
$447,592
|
$447,592
|
DOTTI, GIANPIETRO
|
BAYLOR COLLEGE OF MEDICINE
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
2R01CA116548-06A1
|
$234,457
|
$234,457
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
$3,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
$117,390
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
1U54CA163117-01
|
$503,090
|
$251,545
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
3R01CA129377-04S1
|
$50,222
|
$50,222
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-04
|
$232,601
|
$232,601
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Biology and Therapy of High Risk Neuroblastoma
|
5P01CA081403-12
|
$2,015,534
|
$2,015,534
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome
|
5R33CA152809-02
|
$427,618
|
$427,618
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Role of gangliosides in tumor progression
|
3R01CA061010-16S1
|
$110,968
|
$27,742
|
LADISCH, STEPHAN
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Role of gangliosides in tumor progression
|
4R01CA061010-16
|
$372,530
|
$93,133
|
LADISCH, STEPHAN
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Molecular Genetic Analysis of Human Neuroblastoma
|
5R01CA039771-23
|
$377,150
|
$377,150
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Trk Expression and Inhibition in Human Neuroblastomas
|
5R01CA094194-09
|
$369,828
|
$369,828
|
BRODEUR, GARRETT
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Translational Genomics of MicroRNAs in Neuroblastoma
|
5K08CA136979-03
|
$161,773
|
$161,773
|
Cole, Kristina
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Copy number variations (CNVs) in neuroblastoma
|
5K99CA151869-02
|
$174,960
|
$174,960
|
Diskin, Sharon
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-04
|
$625,023
|
$625,023
|
MARIS, JOHN
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-03
|
$331,098
|
$331,098
|
Mosse, YAEL
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-25
|
$1,147,220
|
$11,472
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Cancer Center Support Grant
|
5P30CA013696-38
|
$3,816,425
|
$76,329
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
3U54CA121852-07S1
|
$134,624
|
$10,770
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
5U54CA121852-07
|
$240,000
|
$19,200
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-38S1
|
$74,998
|
$1,500
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-38S2
|
$139,995
|
$2,800
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
3R01CA124644-04S1
|
$166,126
|
$166,126
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
5R01CA124644-04
|
$324,053
|
$324,053
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
1R01CA148688-01A1
|
$363,125
|
$363,125
|
GEORGE, RANI
|
DANA-FARBER CANCER INSTITUTE
|
|
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma
|
5K08CA128925-05
|
$139,320
|
$139,320
|
Goldsmith, Kelly
|
EMORY UNIVERSITY
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-04
|
$249,581
|
$62,395
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
7U10CA035269-28
|
$705,338
|
$14,107
|
Nikcevich, Daniel
|
ESSENTIA INSTITUTE OF RURAL HEALTH
|
|
EORTC HEADQUARTERS
|
2U10CA011488-41
|
$232,518
|
$6,976
|
SYLVESTER, RICHARD
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-28
|
$450,001
|
$40,500
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
MCG Minority-Based Community Clinical Oncology Program
|
3U10CA107586-08S1
|
$50,000
|
$1,000
|
Jillella, Anand
|
GEORGIA HEALTH SCIENCES UNIV RES INSTIT
|
|
MCG Minority-Based Community Clinical Oncology Program
|
5U10CA107586-08
|
$494,205
|
$9,884
|
Jillella, Anand
|
GEORGIA HEALTH SCIENCES UNIV RES INSTIT
|
|
Iowa Oncology Research Association
|
5U10CA035101-26
|
$822,579
|
$16,452
|
Behrens, Robert
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
Quantitative SPECT for Targeted Radionuclide Therapy
|
2R01CA109234-06A1
|
$393,375
|
$98,344
|
FREY, ERIC
|
JOHNS HOPKINS UNIVERSITY
|
|
Tumor-produced TNF alpha as an inducer of immune resistance and tumor survival
|
5R01CA136663-02
|
$330,091
|
$330,091
|
Levitskaia, Elena
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-48S3
|
$6,995,274
|
$69,953
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-48S4
|
$75,000
|
$750
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
LSUHSC Minority-Based Community Clinical Oncology Program
|
5U10CA063845-13
|
$449,911
|
$8,998
|
VEITH, ROBERT
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
Marshfield Community Clinical Oncology Program
|
5U10CA035412-28
|
$799,787
|
$15,996
|
Weiss, Matthias
|
MARSHFIELD CLINIC RESEARCH FOUNDATION
|
|
Simultaneous Tc-99m-MDP/I-123-MIBG Imaging of Neuroblastoma Using SPECT-CT
|
5R21CA140771-02
|
$186,714
|
$186,714
|
Ouyang, Jinsong
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimizing Immunotherapy for Neuroblastoma after BMT
|
5R01CA100030-08
|
$295,189
|
$295,189
|
JOHNSON, BRYON
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Research Management and Support
|
RMS2011 [E]
|
$335,240,650
|
$77,000
|
N/A
|
National Cancer Institute
|
|
Children's Oncology Group Chair's Grant
|
3U10CA098543-09S3
|
$1,375,035
|
$178,755
|
ADAMSON, PETER
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-09
|
$26,766,352
|
$3,479,626
|
ADAMSON, PETER
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-09
|
$5,780,843
|
$751,510
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Community Clinical Oncology program Research Base
|
5U10CA095861-10
|
$1,464,654
|
$190,405
|
POLLOCK, BRAD
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
2U24CA114766-06
|
$817,102
|
$163,420
|
RAMIREZ, NILSA
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
3U24CA114766-05S2
|
$378,516
|
$75,703
|
Ramirez, Nilsa
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
Total relevant funding to Neuroblastoma for this search: $23,020,533
|